Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05177211 · ClinicalTrials.gov registry record · Phase 2
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
A Phase 2 study of Myeloproliferative Neoplasm and MDS, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT05177211: Active Phase 2 study of Myeloproliferative Neoplasm and MDS, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT05177211 is a Phase 2 study of Myeloproliferative Neoplasm and MDS that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 25 participants, below the 84-participant average among 40 other Myeloproliferative Neoplasm trials with a reported enrollment target (70% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05177211, a Phase 2 study of Myeloproliferative Neoplasm and MDS, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).
Primary Outcome
Response rate of fedratinib in MDS/MPN and CNL. Investigators will measure the proportion of patients achieving a clinical response from baseline to week 24 as defined by Complete Response (CR), Partial Response (PR) or Clinical Benefit (CB) by modified MDS/MPN IWG Proposed response criteria.
Conditions Studied
Interventions
- DRUG Fedratinib Pill
Study Locations (3)
Florida
- Moffitt Cancer Center - Tampa
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
What the registry record for NCT05177211 still lists
NCT05177211 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 84-participant average among 40 other Myeloproliferative Neoplasm trials with a reported enrollment target (70% lower).
The record links to 3 conditions, with Myeloproliferative Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Fedratinib Pill is the first listed.
NCT05177211 reports a single indexed study location in Florida, Michigan, Ohio.
Frequently Asked Questions
What is clinical trial NCT05177211 about?
NCT05177211 is a clinical study titled "Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)". The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).
What is the current status of trial NCT05177211?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2022-03-01. Estimated completion is 2026-04.
What conditions does trial NCT05177211 study?
This clinical trial studies the following conditions: Myeloproliferative Neoplasm, MDS, Chronic Neutrophilic Leukemia.
What interventions are being tested in trial NCT05177211?
The interventions under investigation include: Fedratinib Pill (DRUG).
Who is sponsoring clinical trial NCT05177211?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05177211 being conducted?
This trial has 3 study locations across Florida, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloproliferative Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05177211's enrollment target sits among peer trials
25 34th of 40 higher than 6 of 40 other Myeloproliferative Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myeloproliferative Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
-
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI